Shanghai, China (June 28, 2017) – Shanghai ChemPartner today announced the appointment of Lilly Xu, Ph.D. as Vice President and the Head of DMPK and Exploratory Toxicology at the company headquarters in Shanghai, China.
Dr. Xu has more than 20 years of experience in the area of drug metabolism, pharmacokinetics and toxicology. She was one of the pioneers in developing cultured human hepatocytes as a tool to study metabolism of xenobiotics and induction of P450 isozymes. Prior to joining ChemPartner, Dr. Xu was the Head of the Center of Predictive ADMET at Sanofi/Icagen. She received her Ph.D. in Cell and Molecular Biology from Saint Louis University.
Since the DMPK and Exploratory Toxicology department’s inception in 2006, it has been one of the most rapidly growing business units in the company. This growth is a testament to the high-quality performance and experienced leadership by the scientific team.
“ DMPK is important to Chempartner and our biopharmaceutical clients with respect to drug discovery and development to meet unmet medical needs. We needed an experienced leader to maintain the quality of service that keep our clients satisfied and coming back. Dr. Xu’s expertise, knowledge, and dedication make her a great fit for the team,” said Dr. Wei Tang, President of ChemPartner. Dr. Tang previously served as Senior Vice President, Biology, Biologics, and DMPK and hired Dr. Xu to lead the talented team.
“ChemPartner’s DMPK Exploratory Toxicology integrated service, working in unison with our Chemistry, Biologics, and Biology departments, is the best model for helping our clients to deliver their hits, leads, and candidates in a fast and high quality manner. Our goal at ChemPartner has always been to deliver high quality data to our clients and provide scientific interpretation of the data, thereby helping to solve problems through our expertise in DMPK and toxicology,” said Dr. Xu.
ChemPartner’s DMPK and Exploratory Toxicology department consists of bioanalytical (small and large molecules, discovery, and regulated), in vitro ADME, in vivo pharmacokinetics, and toxicology (non-GLP and partnered GLP) groups. Working closely with Chemistry, Biology/Pharmacology, and Biologics, the department supports translational medicine with experience in formulation development, in vitro and in vivo PK extrapolation, PK/PD correlation, and biomarker analysis including metabolomics.
About ChemPartner
Shanghai ChemPartner is a full-service life science CRO with over 15 years of pharmaceutical research experience. With a team of over 2000 experienced scientists, hundreds of western-trained pharmaceutical industry leaders, and experienced pharmaceutical executive leadership at the helm, ChemPartner is aligned and dedicated to technically and strategically accomplishing the research initiatives of pharma and biotech companies worldwide.
FOR MORE INFORMATION
Livia Legg, MS, Chief Commercial Officer
news@chempartner.com
